PT  - JOURNAL ARTICLE
AU  - Cutts, Alison
AU  - Savoie, Hillary
AU  - Hammer, Michael F.
AU  - Schreiber, John
AU  - Grayson, Celene
AU  - Luzon, Constanza
AU  - Butterfield, Noam
AU  - Pimstone, Simon N.
AU  - Aycardi, Ernesto
AU  - Harden, Cynthia
AU  - Yonan, Chuck
AU  - Jen, Eric
AU  - Nguyen, Trung
AU  - Carmack, Tara
AU  - Haubenberger, Dietrich
TI  - Clinical Characteristics and Treatment Experience of Individuals with SCN8A Developmental and Epileptic Encephalopathy (SCN8A-DEE): Findings from an Online Caregiver Survey
AID  - 10.1101/2021.11.29.21267027
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.29.21267027
4099  - http://medrxiv.org/content/early/2021/12/02/2021.11.29.21267027.short
4100  - http://medrxiv.org/content/early/2021/12/02/2021.11.29.21267027.full
AB  - Purpose SCN8A developmental epileptic encephalopathy (SCN8A-DEE) is a rare and severe genetic epilepsy syndrome characterized by early-onset developmental delay, cognitive impairment, and intractable seizures. Variants in the SCN8A gene are associated with a broad phenotypic spectrum and variable disease severity. A caregiver survey, solicited by the advocacy group The Cute Syndrome Foundation (TCSF), was conducted to gather information on the demographics/disease presentation, seizure history, and treatment of patients with SCN8A-related epilepsies.Methods A 36-question online survey was developed to obtain de-identified data from caregivers of children with SCN8A-related epilepsy. The survey included questions on genetic diagnosis, disease manifestations/comorbidities, seizure severity/type, current/prior use of antiseizure medicines (ASMs), and best/worst treatments per caregiver perception.Results In total, 116 survey responses (87 USA, 12 Canada, 12 UK, 5 Australia) were included in the quantitative analysis. Generalized tonic/clonic was the most common seizure type at onset and time of survey; absence and partial/focal seizures were also common. Most patients (77%) were currently taking ≥2 ASMs; 50% had previously tried and stopped ≥4 ASMs. Sodium channel blockers (oxcarbazepine, phenytoin, lamotrigine) provided the best subjective seizure control and quality of life.Conclusion The SCN8A-DEE patient population is heterogeneous and difficult to treat, with high seizure burden and multiple comorbidities. The high proportion of patients who previously tried and stopped ASMs indicates a large unmet treatment need. Further collaboration between families, caregivers, patient advocates, clinicians, researchers, and industry can increase awareness and understanding of SCN8A-related epilepsies, improve clinical trial design, and potentially improve patient outcomes.HIGHLIGHTSThis is the first survey-based study of caregiver experiences in SCN8A-DEECaregivers report a broad range of seizure types and genetic variants in patientsPatients generally suffer from high seizure burden and multiple comorbiditiesResults suggest new treatments and standardized treatment protocols are neededPatient-centered research may improve awareness of SCN8A-DEE and patient outcomesCompeting Interest StatementNo competing interestes with payments from third parties. Xenon Pharmaceuticals employees receive salaries from Xenon and may hold stock and stock options in the company. Neurocrine Bioscience employees receive salaries from Neurocrine and may hold stock and stock options in the company. John Schreiber is a consultant for Neurocrine and Xenon. Hillary Savoie and Michael Hammer are or have been consultants for Neurocrine and Xenon and their respective non-profits have received grants and/or other funding from Neurocrine and Xenon.Funding StatementStudy conduct was funded by Xenon Pharmaceuticals. Subsequent analysis presented in this manuscript as well as manuscript preparation were funded by Neurocrine Biosciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Veritas IRB gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript